Global and United States Antibacterial (Drug) Resistance Market Insights, Forecast to 2027
SKU ID : QYR-18739120 | Publishing Date : 13-Jul-2021 | No. of pages : 169
Detailed TOC of Global and United States Antibacterial (Drug) Resistance Market Insights, Forecast to 2027
1 Study Coverage1.1 Antibacterial (Drug) Resistance Product Introduction
1.2 Market by Type
1.2.1 Global Antibacterial (Drug) Resistance Market Size Growth Rate by Type
1.2.2 Telavancin (Vibativ)
1.2.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
1.2.4 Fidaxomicin (Dificid / Dificlir)
1.2.5 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
1.2.6 Dalbavancin (Dalvance/ Xydalba)
1.2.7 Tedizolid Phosphate (Sivextro)
1.2.8 Oritavancin (Orbactiv/ Nuvocid)
1.2.9 Ceftolozane-Tazobactam (Zerbaxa)
1.2.10 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
1.2.11 PHASE III DRUGS
1.3 Market by Indication
1.3.1 Global Antibacterial (Drug) Resistance Market Size Growth Rate by Indication
1.3.2 Complicated Urinary Tract Infection (CUTI)
1.3.3 Complicated Intra-Abdominal Infections (CIAI)
1.3.4 Blood Stream Infections (BSI)
1.3.5 Clostridium Difficile Infections (CDI)
1.3.6 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
1.3.7 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
1.3.8 Community Acquired Bacterial Pneumonia (CABP)
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Antibacterial (Drug) Resistance Market Size, Estimates and Forecasts
2.1.1 Global Antibacterial (Drug) Resistance Revenue 2016-2027
2.1.2 Global Antibacterial (Drug) Resistance Sales 2016-2027
2.2 Global Antibacterial (Drug) Resistance, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Antibacterial (Drug) Resistance Historical Market Size by Region (2016-2021)
2.3.1 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Antibacterial (Drug) Resistance Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Antibacterial (Drug) Resistance Sales Forecast by Region (2022-2027)
2.4.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Region (2022-2027)
3 Global Antibacterial (Drug) Resistance Competitor Landscape by Players
3.1 Global Top Antibacterial (Drug) Resistance Manufacturers by Sales
3.1.1 Global Antibacterial (Drug) Resistance Sales by Manufacturer (2016-2021)
3.1.2 Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Antibacterial (Drug) Resistance Manufacturers by Revenue
3.2.1 Key Antibacterial (Drug) Resistance Manufacturers Covered: Ranking by Revenue
3.2.2 Global Antibacterial (Drug) Resistance Revenue by Manufacturers (2016-2021)
3.2.3 Global Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Antibacterial (Drug) Resistance Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Antibacterial (Drug) Resistance Revenue in 2020
3.2.6 Global Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Antibacterial (Drug) Resistance Price by Manufacturers
3.4 Global Antibacterial (Drug) Resistance Manufacturing Base Distribution, Product Types
3.4.1 Antibacterial (Drug) Resistance Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Antibacterial (Drug) Resistance Product Type
3.4.3 Date of International Manufacturers Enter into Antibacterial (Drug) Resistance Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2016-2027)
4.1 Global Antibacterial (Drug) Resistance Market Size by Type (2016-2021)
4.1.1 Global Antibacterial (Drug) Resistance Sales by Type (2016-2021)
4.1.2 Global Antibacterial (Drug) Resistance Revenue by Type (2016-2021)
4.1.3 Antibacterial (Drug) Resistance Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Antibacterial (Drug) Resistance Market Size Forecast by Type (2022-2027)
4.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Type (2022-2027)
4.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Type (2022-2027)
4.2.3 Antibacterial (Drug) Resistance Average Selling Price (ASP) Forecast by Type (2022-2027)
5 Breakdown Data by Indication (2016-2027)
5.1 Global Antibacterial (Drug) Resistance Market Size by Indication (2016-2021)
5.1.1 Global Antibacterial (Drug) Resistance Sales by Indication (2016-2021)
5.1.2 Global Antibacterial (Drug) Resistance Revenue by Indication (2016-2021)
5.1.3 Antibacterial (Drug) Resistance Price by Indication (2016-2021)
5.2 Antibacterial (Drug) Resistance Market Size Forecast by Indication (2022-2027)
5.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Indication (2022-2027)
5.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Indication (2022-2027)
5.2.3 Global Antibacterial (Drug) Resistance Price Forecast by Indication (2022-2027)
6 United States by Players, Type and Indication
6.1 United States Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027
6.1.1 United States Antibacterial (Drug) Resistance Sales YoY Growth 2016-2027
6.1.2 United States Antibacterial (Drug) Resistance Revenue YoY Growth 2016-2027
6.1.3 United States Antibacterial (Drug) Resistance Market Share in Global Market 2016-2027
6.2 United States Antibacterial (Drug) Resistance Market Size by Players (International and Local Players)
6.2.1 United States Top Antibacterial (Drug) Resistance Players by Sales (2016-2021)
6.2.2 United States Top Antibacterial (Drug) Resistance Players by Revenue (2016-2021)
6.3 United States Antibacterial (Drug) Resistance Historic Market Review by Type (2016-2021)
6.3.1 United States Antibacterial (Drug) Resistance Sales Market Share by Type (2016-2021)
6.3.2 United States Antibacterial (Drug) Resistance Revenue Market Share by Type (2016-2021)
6.3.3 United States Antibacterial (Drug) Resistance Price by Type (2016-2021)
6.4 United States Antibacterial (Drug) Resistance Market Estimates and Forecasts by Type (2022-2027)
6.4.1 United States Antibacterial (Drug) Resistance Sales Forecast by Type (2022-2027)
6.4.2 United States Antibacterial (Drug) Resistance Revenue Forecast by Type (2022-2027)
6.4.3 United States Antibacterial (Drug) Resistance Price Forecast by Type (2022-2027)
6.5 United States Antibacterial (Drug) Resistance Historic Market Review by Indication (2016-2021)
6.5.1 United States Antibacterial (Drug) Resistance Sales Market Share by Indication (2016-2021)
6.5.2 United States Antibacterial (Drug) Resistance Revenue Market Share by Indication (2016-2021)
6.5.3 United States Antibacterial (Drug) Resistance Price by Indication (2016-2021)
6.6 United States Antibacterial (Drug) Resistance Market Estimates and Forecasts by Indication (2022-2027)
6.6.1 United States Antibacterial (Drug) Resistance Sales Forecast by Indication (2022-2027)
6.6.2 United States Antibacterial (Drug) Resistance Revenue Forecast by Indication (2022-2027)
6.6.3 United States Antibacterial (Drug) Resistance Price Forecast by Indication (2022-2027)
7 North America
7.1 North America Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027
7.2 North America Antibacterial (Drug) Resistance Market Facts & Figures by Country
7.2.1 North America Antibacterial (Drug) Resistance Sales by Country (2016-2021)
7.2.2 North America Antibacterial (Drug) Resistance Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027
8.2 Asia Pacific Antibacterial (Drug) Resistance Market Facts & Figures by Region
8.2.1 Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2016-2021)
8.2.2 Asia Pacific Antibacterial (Drug) Resistance Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam
9 Europe
9.1 Europe Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027
9.2 Europe Antibacterial (Drug) Resistance Market Facts & Figures by Country
9.2.1 Europe Antibacterial (Drug) Resistance Sales by Country (2016-2021)
9.2.2 Europe Antibacterial (Drug) Resistance Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027
10.2 Latin America Antibacterial (Drug) Resistance Market Facts & Figures by Country
10.2.1 Latin America Antibacterial (Drug) Resistance Sales by Country (2016-2021)
10.2.2 Latin America Antibacterial (Drug) Resistance Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Antibacterial (Drug) Resistance Market Facts & Figures by Country
11.2.1 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2016-2021)
11.2.2 Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Melinta Therapeutics
12.1.1 Melinta Therapeutics Corporation Information
12.1.2 Melinta Therapeutics Description and Business Overview
12.1.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Products Offered
12.1.5 Melinta Therapeutics Recent Development
12.2 Allergan
12.2.1 Allergan Corporation Information
12.2.2 Allergan Description and Business Overview
12.2.3 Allergan Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Allergan Antibacterial (Drug) Resistance Products Offered
12.2.5 Allergan Recent Development
12.3 Merck
12.3.1 Merck Corporation Information
12.3.2 Merck Description and Business Overview
12.3.3 Merck Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Merck Antibacterial (Drug) Resistance Products Offered
12.3.5 Merck Recent Development
12.4 Abbott Laboratories
12.4.1 Abbott Laboratories Corporation Information
12.4.2 Abbott Laboratories Description and Business Overview
12.4.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Abbott Laboratories Antibacterial (Drug) Resistance Products Offered
12.4.5 Abbott Laboratories Recent Development
12.5 Pfizer
12.5.1 Pfizer Corporation Information
12.5.2 Pfizer Description and Business Overview
12.5.3 Pfizer Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Pfizer Antibacterial (Drug) Resistance Products Offered
12.5.5 Pfizer Recent Development
12.6 GSK
12.6.1 GSK Corporation Information
12.6.2 GSK Description and Business Overview
12.6.3 GSK Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.6.4 GSK Antibacterial (Drug) Resistance Products Offered
12.6.5 GSK Recent Development
12.7 PENDOPHARM
12.7.1 PENDOPHARM Corporation Information
12.7.2 PENDOPHARM Description and Business Overview
12.7.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.7.4 PENDOPHARM Antibacterial (Drug) Resistance Products Offered
12.7.5 PENDOPHARM Recent Development
12.8 Absynth Biologics
12.8.1 Absynth Biologics Corporation Information
12.8.2 Absynth Biologics Description and Business Overview
12.8.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Absynth Biologics Antibacterial (Drug) Resistance Products Offered
12.8.5 Absynth Biologics Recent Development
12.9 Achaogen
12.9.1 Achaogen Corporation Information
12.9.2 Achaogen Description and Business Overview
12.9.3 Achaogen Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Achaogen Antibacterial (Drug) Resistance Products Offered
12.9.5 Achaogen Recent Development
12.10 Acino Holdings
12.10.1 Acino Holdings Corporation Information
12.10.2 Acino Holdings Description and Business Overview
12.10.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Acino Holdings Antibacterial (Drug) Resistance Products Offered
12.10.5 Acino Holdings Recent Development
12.11 Melinta Therapeutics
12.11.1 Melinta Therapeutics Corporation Information
12.11.2 Melinta Therapeutics Description and Business Overview
12.11.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Melinta Therapeutics Antibacterial (Drug) Resistance Products Offered
12.11.5 Melinta Therapeutics Recent Development
12.12 Austell Laboratories
12.12.1 Austell Laboratories Corporation Information
12.12.2 Austell Laboratories Description and Business Overview
12.12.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Austell Laboratories Products Offered
12.12.5 Austell Laboratories Recent Development
12.13 Assembly Biosciences
12.13.1 Assembly Biosciences Corporation Information
12.13.2 Assembly Biosciences Description and Business Overview
12.13.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Assembly Biosciences Products Offered
12.13.5 Assembly Biosciences Recent Development
12.14 Arpida
12.14.1 Arpida Corporation Information
12.14.2 Arpida Description and Business Overview
12.14.3 Arpida Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Arpida Products Offered
12.14.5 Arpida Recent Development
12.15 Demuris
12.15.1 Demuris Corporation Information
12.15.2 Demuris Description and Business Overview
12.15.3 Demuris Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Demuris Products Offered
12.15.5 Demuris Recent Development
12.16 Evolva Holding
12.16.1 Evolva Holding Corporation Information
12.16.2 Evolva Holding Description and Business Overview
12.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.16.4 Evolva Holding Products Offered
12.16.5 Evolva Holding Recent Development
12.17 ContraFect
12.17.1 ContraFect Corporation Information
12.17.2 ContraFect Description and Business Overview
12.17.3 ContraFect Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.17.4 ContraFect Products Offered
12.17.5 ContraFect Recent Development
12.18 Cerexa
12.18.1 Cerexa Corporation Information
12.18.2 Cerexa Description and Business Overview
12.18.3 Cerexa Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.18.4 Cerexa Products Offered
12.18.5 Cerexa Recent Development
12.19 InterMune
12.19.1 InterMune Corporation Information
12.19.2 InterMune Description and Business Overview
12.19.3 InterMune Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.19.4 InterMune Products Offered
12.19.5 InterMune Recent Development
12.20 Isis Pharmaceuticals
12.20.1 Isis Pharmaceuticals Corporation Information
12.20.2 Isis Pharmaceuticals Description and Business Overview
12.20.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.20.4 Isis Pharmaceuticals Products Offered
12.20.5 Isis Pharmaceuticals Recent Development
12.21 Lyndra
12.21.1 Lyndra Corporation Information
12.21.2 Lyndra Description and Business Overview
12.21.3 Lyndra Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.21.4 Lyndra Products Offered
12.21.5 Lyndra Recent Development
12.22 Microbecide
12.22.1 Microbecide Corporation Information
12.22.2 Microbecide Description and Business Overview
12.22.3 Microbecide Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.22.4 Microbecide Products Offered
12.22.5 Microbecide Recent Development
12.23 Morphochem
12.23.1 Morphochem Corporation Information
12.23.2 Morphochem Description and Business Overview
12.23.3 Morphochem Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.23.4 Morphochem Products Offered
12.23.5 Morphochem Recent Development
12.24 Nabriva Therapeutics
12.24.1 Nabriva Therapeutics Corporation Information
12.24.2 Nabriva Therapeutics Description and Business Overview
12.24.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.24.4 Nabriva Therapeutics Products Offered
12.24.5 Nabriva Therapeutics Recent Development
12.25 NanoSafe Coatings
12.25.1 NanoSafe Coatings Corporation Information
12.25.2 NanoSafe Coatings Description and Business Overview
12.25.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.25.4 NanoSafe Coatings Products Offered
12.25.5 NanoSafe Coatings Recent Development
12.26 Novexel
12.26.1 Novexel Corporation Information
12.26.2 Novexel Description and Business Overview
12.26.3 Novexel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.26.4 Novexel Products Offered
12.26.5 Novexel Recent Development
12.27 Osel
12.27.1 Osel Corporation Information
12.27.2 Osel Description and Business Overview
12.27.3 Osel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.27.4 Osel Products Offered
12.27.5 Osel Recent Development
12.28 VenatoRx Pharmaceuticals
12.28.1 VenatoRx Pharmaceuticals Corporation Information
12.28.2 VenatoRx Pharmaceuticals Description and Business Overview
12.28.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.28.4 VenatoRx Pharmaceuticals Products Offered
12.28.5 VenatoRx Pharmaceuticals Recent Development
12.29 AAIPharma Services
12.29.1 AAIPharma Services Corporation Information
12.29.2 AAIPharma Services Description and Business Overview
12.29.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.29.4 AAIPharma Services Products Offered
12.29.5 AAIPharma Services Recent Development
12.30 ANTABIO
12.30.1 ANTABIO Corporation Information
12.30.2 ANTABIO Description and Business Overview
12.30.3 ANTABIO Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021)
12.30.4 ANTABIO Products Offered
12.30.5 ANTABIO Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Antibacterial (Drug) Resistance Industry Trends
13.2 Antibacterial (Drug) Resistance Market Drivers
13.3 Antibacterial (Drug) Resistance Market Challenges
13.4 Antibacterial (Drug) Resistance Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Antibacterial (Drug) Resistance Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Figures, Tables and Charts Available in Global and United States Antibacterial (Drug) Resistance Market Insights, Forecast to 2027
List of TablesTable 1. Global Antibacterial (Drug) Resistance Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Telavancin (Vibativ)
Table 3. Major Manufacturers of Ceftaroline Fosamil (Teflaro/ Zinforo)
Table 4. Major Manufacturers of Fidaxomicin (Dificid / Dificlir)
Table 5. Major Manufacturers of Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Table 6. Major Manufacturers of Dalbavancin (Dalvance/ Xydalba)
Table 7. Major Manufacturers of Tedizolid Phosphate (Sivextro)
Table 8. Major Manufacturers of Oritavancin (Orbactiv/ Nuvocid)
Table 9. Major Manufacturers of Ceftolozane-Tazobactam (Zerbaxa)
Table 10. Major Manufacturers of Ceftazidime-Avibactam (Avycaz/ Zavicefta)
Table 11. Major Manufacturers of PHASE III DRUGS
Table 12. Global Antibacterial (Drug) Resistance Market Size Growth Rate by Indication (2021-2027) & (K Units)
Table 13. Global Antibacterial (Drug) Resistance Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027
Table 14. Global Antibacterial (Drug) Resistance Sales by Regions (2016-2021) & (K Units)
Table 15. Global Antibacterial (Drug) Resistance Sales Market Share by Regions (2016-2021)
Table 16. Global Antibacterial (Drug) Resistance Revenue by Regions (2016-2021) & (US$ Million)
Table 17. Global Antibacterial (Drug) Resistance Sales Forecast by Region (2022-2027) & (K Units)
Table 18. Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Region (2022-2027)
Table 19. Global Antibacterial (Drug) Resistance Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 20. Global Antibacterial (Drug) Resistance Revenue Market Share Forecast by Region (2022-2027)
Table 21. Global Antibacterial (Drug) Resistance Sales by Manufacturers (2016-2021) (K Units)
Table 22. Global Antibacterial (Drug) Resistance Sales Share by Manufacturers (2016-2021)
Table 23. Ranking of Global Top Antibacterial (Drug) Resistance Manufacturers by Revenue (US$ Million) in 2020
Table 24. Antibacterial (Drug) Resistance Revenue by Manufacturers (2016-2021) (US$ Million)
Table 25. Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2016-2021)
Table 26. Global Antibacterial (Drug) Resistance Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 27. Global Antibacterial (Drug) Resistance by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibacterial (Drug) Resistance as of 2020)
Table 28. Key Manufacturers Antibacterial (Drug) Resistance Price (2016-2021) (USD/Unit)
Table 29. Antibacterial (Drug) Resistance Manufacturers Manufacturing Base Distribution and Headquarters
Table 30. Manufacturers Antibacterial (Drug) Resistance Product Type
Table 31. Date of International Manufacturers Enter into Antibacterial (Drug) Resistance Market
Table 32. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 33. Global Antibacterial (Drug) Resistance Sales by Type (2016-2021) (K Units)
Table 34. Global Antibacterial (Drug) Resistance Sales Share by Type (2016-2021)
Table 35. Global Antibacterial (Drug) Resistance Revenue by Type (2016-2021) (US$ Million)
Table 36. Global Antibacterial (Drug) Resistance Revenue Share by Type (2016-2021)
Table 37. Antibacterial (Drug) Resistance Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Table 38. Global Antibacterial (Drug) Resistance Sales Forecast by Type (2022-2027) & (K Units)
Table 39. Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Type (2022-2027)
Table 40. Global Antibacterial (Drug) Resistance Revenue Forecast V (2022-2027) & (US$ Million)
Table 41. Global Antibacterial (Drug) Resistance Revenue Market Share Forecast by Type (2022-2027)
Table 42. Global Antibacterial (Drug) Resistance Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Unit)
Table 43. Global Antibacterial (Drug) Resistance Sales by Indication (2016-2021) (K Units)
Table 44. Global Antibacterial (Drug) Resistance Sales Share by Indication (2016-2021)
Table 45. Global Antibacterial (Drug) Resistance Revenue by Indication (2016-2021) (US$ Million)
Table 46. Global Antibacterial (Drug) Resistance Revenue Share by Indication (2016-2021)
Table 47. Antibacterial (Drug) Resistance Average Selling Price (ASP) by Indication (2016-2021) & (USD/Unit)
Table 48. Global Antibacterial (Drug) Resistance Sales Forecast by Indication (2022-2027) & (K Units)
Table 49. Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Indication (2022-2027)
Table 50. Global Antibacterial (Drug) Resistance Revenue Forecast by Indication (2022-2027) & (US$ Million)
Table 51. Global Antibacterial (Drug) Resistance Revenue Market Share Forecast by Indication (2022-2027)
Table 52. Global Antibacterial (Drug) Resistance Average Selling Price (ASP) Forecast by Indication (2022-2027) & (USD/Unit)
Table 53. United States Antibacterial (Drug) Resistance Sales (K Units) of Key Companies (2016-2021)
Table 54. United States Antibacterial (Drug) Resistance Sales Share by Company (2016-2021)
Table 55. United States Antibacterial (Drug) Resistance Revenue (US$ Million) by Company (2016-2021)
Table 56. United States Antibacterial (Drug) Resistance Revenue Share by Company (2016-2021)
Table 57. United States Antibacterial (Drug) Resistance Sales (K Units) by Type (2016-2021)
Table 58. United States Antibacterial (Drug) Resistance Sales Share by Type (2016-2021)
Table 59. United States Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Type (2016-2021)
Table 60. United States Antibacterial (Drug) Resistance Price (USD/Unit) by Type (2016-2021)
Table 61. United States Antibacterial (Drug) Resistance Sales (K Units) by Type (2022-2027)
Table 62. United States Antibacterial (Drug) Resistance Sales Share by Type (2022-2027)
Table 63. United States Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Type (2022-2027)
Table 64. United States Antibacterial (Drug) Resistance Revenue Share by Type (2022-2027)
Table 65. United States Antibacterial (Drug) Resistance Price (USD/Unit) by Type (2022-2027)
Table 66. United States Antibacterial (Drug) Resistance Sales (K Units) by Indication (2016-2021)
Table 67. United States Antibacterial (Drug) Resistance Sales Share by Indication (2016-2021)
Table 68. United States Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Indication (2016-2021)
Table 69. United States Antibacterial (Drug) Resistance Price (USD/Unit) by Indication (2016-2021)
Table 70. United States Antibacterial (Drug) Resistance Sales (K Units) by Indication (2022-2027)
Table 71. United States Antibacterial (Drug) Resistance Sales Share by Indication (2022-2027)
Table 72. United States Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Indication (2022-2027)
Table 73. United States Antibacterial (Drug) Resistance Revenue Share by Indication (2022-2027)
Table 74. United States Antibacterial (Drug) Resistance Price (USD/Unit) by Indication (2022-2027)
Table 75. North America Antibacterial (Drug) Resistance Sales by Country (2016-2021) & (K Units)
Table 76. North America Antibacterial (Drug) Resistance Sales Market Share by Country (2016-2021)
Table 77. North America Antibacterial (Drug) Resistance Revenue by Country (2016-2021) & (US$ Million)
Table 78. North America Antibacterial (Drug) Resistance Revenue Market Share by Country (2016-2021)
Table 79. Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2016-2021) & (K Units)
Table 80. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Region (2016-2021)
Table 81. Asia Pacific Antibacterial (Drug) Resistance Revenue by Region (2016-2021) & (US$ Million)
Table 82. Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Region (2016-2021)
Table 83. Europe Antibacterial (Drug) Resistance Sales by Country (2016-2021) & (K Units)
Table 84. Europe Antibacterial (Drug) Resistance Sales Market Share by Country (2016-2021)
Table 85. Europe Antibacterial (Drug) Resistance Revenue by Country (2016-2021) & (US$ Million)
Table 86. Europe Antibacterial (Drug) Resistance Revenue Market Share by Country (2016-2021)
Table 87. Latin America Antibacterial (Drug) Resistance Sales by Country (2016-2021) & (K Units)
Table 88. Latin America Antibacterial (Drug) Resistance Sales Market Share by Country (2016-2021)
Table 89. Latin Americaa Antibacterial (Drug) Resistance Revenue by Country (2016-2021) & (US$ Million)
Table 90. Latin America Antibacterial (Drug) Resistance Revenue Market Share by Country (2016-2021)
Table 91. Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2016-2021) & (K Units)
Table 92. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Country (2016-2021)
Table 93. Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2016-2021) & (US$ Million)
Table 94. Middle East and Africa Antibacterial (Drug) Resistance Revenue Market Share by Country (2016-2021)
Table 95. Melinta Therapeutics Corporation Information
Table 96. Melinta Therapeutics Description and Business Overview
Table 97. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 98. Melinta Therapeutics Antibacterial (Drug) Resistance Product
Table 99. Melinta Therapeutics Recent Development
Table 100. Allergan Corporation Information
Table 101. Allergan Description and Business Overview
Table 102. Allergan Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 103. Allergan Product
Table 104. Allergan Recent Development
Table 105. Merck Corporation Information
Table 106. Merck Description and Business Overview
Table 107. Merck Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 108. Merck Product
Table 109. Merck Recent Development
Table 110. Abbott Laboratories Corporation Information
Table 111. Abbott Laboratories Description and Business Overview
Table 112. Abbott Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 113. Abbott Laboratories Product
Table 114. Abbott Laboratories Recent Development
Table 115. Pfizer Corporation Information
Table 116. Pfizer Description and Business Overview
Table 117. Pfizer Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 118. Pfizer Product
Table 119. Pfizer Recent Development
Table 120. GSK Corporation Information
Table 121. GSK Description and Business Overview
Table 122. GSK Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 123. GSK Product
Table 124. GSK Recent Development
Table 125. PENDOPHARM Corporation Information
Table 126. PENDOPHARM Description and Business Overview
Table 127. PENDOPHARM Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 128. PENDOPHARM Product
Table 129. PENDOPHARM Recent Development
Table 130. Absynth Biologics Corporation Information
Table 131. Absynth Biologics Description and Business Overview
Table 132. Absynth Biologics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 133. Absynth Biologics Product
Table 134. Absynth Biologics Recent Development
Table 135. Achaogen Corporation Information
Table 136. Achaogen Description and Business Overview
Table 137. Achaogen Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 138. Achaogen Product
Table 139. Achaogen Recent Development
Table 140. Acino Holdings Corporation Information
Table 141. Acino Holdings Description and Business Overview
Table 142. Acino Holdings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 143. Acino Holdings Product
Table 144. Acino Holdings Recent Development
Table 145. Aventis Pharma Corporation Information
Table 146. Aventis Pharma Description and Business Overview
Table 147. Aventis Pharma Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 148. Aventis Pharma Product
Table 149. Aventis Pharma Recent Development
Table 150. Austell Laboratories Corporation Information
Table 151. Austell Laboratories Description and Business Overview
Table 152. Austell Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 153. Austell Laboratories Product
Table 154. Austell Laboratories Recent Development
Table 155. Assembly Biosciences Corporation Information
Table 156. Assembly Biosciences Description and Business Overview
Table 157. Assembly Biosciences Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 158. Assembly Biosciences Product
Table 159. Assembly Biosciences Recent Development
Table 160. Arpida Corporation Information
Table 161. Arpida Description and Business Overview
Table 162. Arpida Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 163. Arpida Product
Table 164. Arpida Recent Development
Table 165. Demuris Corporation Information
Table 166. Demuris Description and Business Overview
Table 167. Demuris Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 168. Demuris Product
Table 169. Demuris Recent Development
Table 170. Evolva Holding Corporation Information
Table 171. Evolva Holding Description and Business Overview
Table 172. Evolva Holding Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 173. Evolva Holding Product
Table 174. Evolva Holding Recent Development
Table 175. ContraFect Corporation Information
Table 176. ContraFect Description and Business Overview
Table 177. ContraFect Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 178. ContraFect Product
Table 179. ContraFect Recent Development
Table 180. Cerexa Corporation Information
Table 181. Cerexa Description and Business Overview
Table 182. Cerexa Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 183. Cerexa Product
Table 184. Cerexa Recent Development
Table 185. InterMune Corporation Information
Table 186. InterMune Description and Business Overview
Table 187. InterMune Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 188. InterMune Product
Table 189. InterMune Recent Development
Table 190. Isis Pharmaceuticals Corporation Information
Table 191. Isis Pharmaceuticals Description and Business Overview
Table 192. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 193. Isis Pharmaceuticals Product
Table 194. Isis Pharmaceuticals Recent Development
Table 195. Lyndra Corporation Information
Table 196. Lyndra Description and Business Overview
Table 197. Lyndra Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 198. Lyndra Product
Table 199. Lyndra Recent Development
Table 200. Microbecide Corporation Information
Table 201. Microbecide Description and Business Overview
Table 202. Microbecide Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 203. Microbecide Product
Table 204. Microbecide Recent Development
Table 205. Morphochem Corporation Information
Table 206. Morphochem Description and Business Overview
Table 207. Morphochem Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 208. Morphochem Product
Table 209. Morphochem Recent Development
Table 210. Nabriva Therapeutics Corporation Information
Table 211. Nabriva Therapeutics Description and Business Overview
Table 212. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 213. Nabriva Therapeutics Product
Table 214. Nabriva Therapeutics Recent Development
Table 215. NanoSafe Coatings Corporation Information
Table 216. NanoSafe Coatings Description and Business Overview
Table 217. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 218. NanoSafe Coatings Product
Table 219. NanoSafe Coatings Recent Development
Table 220. Novexel Corporation Information
Table 221. Novexel Description and Business Overview
Table 222. Novexel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 223. Novexel Product
Table 224. Novexel Recent Development
Table 225. Osel Corporation Information
Table 226. Osel Description and Business Overview
Table 227. Osel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 228. Osel Product
Table 229. Osel Recent Development
Table 230. VenatoRx Pharmaceuticals Corporation Information
Table 231. VenatoRx Pharmaceuticals Description and Business Overview
Table 232. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 233. VenatoRx Pharmaceuticals Product
Table 234. VenatoRx Pharmaceuticals Recent Development
Table 235. AAIPharma Services Corporation Information
Table 236. AAIPharma Services Description and Business Overview
Table 237. AAIPharma Services Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 238. AAIPharma Services Product
Table 239. AAIPharma Services Recent Development
Table 240. ANTABIO Corporation Information
Table 241. ANTABIO Description and Business Overview
Table 242. ANTABIO Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 243. ANTABIO Product
Table 244. ANTABIO Recent Development
Table 245. Antibacterial (Drug) Resistance Market Trends
Table 246. Antibacterial (Drug) Resistance Market Drivers
Table 247. Antibacterial (Drug) Resistance Market Challenges
Table 248. Antibacterial (Drug) Resistance Market Restraints
Table 249. Antibacterial (Drug) Resistance Customers List
Table 250. Antibacterial (Drug) Resistance Distributors List
Table 251. Research Programs/Design for This Report
Table 252. Key Data Information from Secondary Sources
Table 253. Key Data Information from Primary Sources
List of Figures
Figure 1. Antibacterial (Drug) Resistance Product Picture
Figure 2. Global Antibacterial (Drug) Resistance Sales Market Share by Type in 2020 & 2027
Figure 3. Telavancin (Vibativ) Product Picture
Figure 4. Ceftaroline Fosamil (Teflaro/ Zinforo) Product Picture
Figure 5. Fidaxomicin (Dificid / Dificlir) Product Picture
Figure 6. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Product Picture
Figure 7. Dalbavancin (Dalvance/ Xydalba) Product Picture
Figure 8. Tedizolid Phosphate (Sivextro) Product Picture
Figure 9. Oritavancin (Orbactiv/ Nuvocid) Product Picture
Figure 10. Ceftolozane-Tazobactam (Zerbaxa) Product Picture
Figure 11. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Product Picture
Figure 12. PHASE III DRUGS Product Picture
Figure 13. Global Antibacterial (Drug) Resistance Sales Market Share by Indication in 2020 & 2027
Figure 14. Complicated Urinary Tract Infection (CUTI)
Figure 15. Complicated Intra-Abdominal Infections (CIAI)
Figure 16. Blood Stream Infections (BSI)
Figure 17. Clostridium Difficile Infections (CDI)
Figure 18. Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Figure 19. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Figure 20. Community Acquired Bacterial Pneumonia (CABP)
Figure 21. Antibacterial (Drug) Resistance Report Years Considered
Figure 22. Global Antibacterial (Drug) Resistance Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 23. Global Antibacterial (Drug) Resistance Market Size 2016-2027 (US$ Million)
Figure 24. Global Antibacterial (Drug) Resistance Sales 2016-2027 (K Units)
Figure 25. Global Antibacterial (Drug) Resistance Market Size Market Share by Region: 2021 Versus 2027
Figure 26. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2016-2021)
Figure 27. Global Antibacterial (Drug) Resistance Sales Market Share by Region in 2020
Figure 28. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2016-2021)
Figure 29. Global Antibacterial (Drug) Resistance Revenue Market Share by Region in 2020
Figure 30. Global Antibacterial (Drug) Resistance Sales Share by Manufacturer in 2020
Figure 31. The Top 10 and 5 Players Market Share by Antibacterial (Drug) Resistance Revenue in 2020
Figure 32. Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 33. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2016-2021)
Figure 34. Global Antibacterial (Drug) Resistance Sales Market Share by Type in 2020
Figure 35. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2016-2021)
Figure 36. Global Antibacterial (Drug) Resistance Revenue Market Share by Type in 2020
Figure 37. Global Antibacterial (Drug) Resistance Sales Market Share by Indication (2016-2021)
Figure 38. Global Antibacterial (Drug) Resistance Sales Market Share by Indication in 2020
Figure 39. Global Antibacterial (Drug) Resistance Revenue Market Share by Indication (2016-2021)
Figure 40. Global Antibacterial (Drug) Resistance Revenue Market Share by Indication in 2020
Figure 41. United States Antibacterial (Drug) Resistance Sales Growth Rate 2016-2027 (K Units)
Figure 42. United States Antibacterial (Drug) Resistance Revenue Growth Rate 2016-2027 (US$ Million)
Figure 43. United States Antibacterial (Drug) Resistance Market Share in Global Market 2016-2027
Figure 44. United States 5 and 10 Largest Antibacterial (Drug) Resistance Players Market Share by Revenue in Antibacterial (Drug) Resistance in 2020
Figure 45. United States Antibacterial (Drug) Resistance Revenue Share by Type (2016-2021)
Figure 46. United States Antibacterial (Drug) Resistance Revenue Growth Rate by Type in 2016 & 2020
Figure 47. United States Antibacterial (Drug) Resistance Revenue Share by Indication (2016-2021)
Figure 48. United States Antibacterial (Drug) Resistance Revenue Growth Rate by Indication in 2016 & 2020
Figure 49. North America Antibacterial (Drug) Resistance Sales Growth Rate 2016-2021 (K Units)
Figure 50. North America Antibacterial (Drug) Resistance Revenue Growth Rate 2016-2021 (US$ Million)
Figure 51. North America Antibacterial (Drug) Resistance Sales Market Share by Country in 2020
Figure 52. North America Antibacterial (Drug) Resistance Revenue Market Share by Country in 2020
Figure 53. U.S. Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 54. U.S. Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 55. Canada Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 56. Canada Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 57. Europe Antibacterial (Drug) Resistance Sales Growth Rate 2016-2021 (K Units)
Figure 58. Europe Antibacterial (Drug) Resistance Revenue Growth Rate 2016-2021 (US$ Million)
Figure 59. Europe Antibacterial (Drug) Resistance Sales Market Share by Country in 2020
Figure 60. Europe Antibacterial (Drug) Resistance Revenue Market Share by Country in 2020
Figure 61. Germany Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 62. Germany Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 63. France Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 64. France Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 65. U.K. Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 66. U.K. Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 67. Italy Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 68. Italy Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 69. Russia Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 70. Russia Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 71. Asia Pacific Antibacterial (Drug) Resistance Sales Growth Rate 2016-2021 (K Units)
Figure 72. Asia Pacific Antibacterial (Drug) Resistance Revenue Growth Rate 2016-2021 (US$ Million)
Figure 73. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Region in 2020
Figure 74. Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Region in 2020
Figure 75. China Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 76. China Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 77. Japan Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 78. Japan Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 79. South Korea Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 80. South Korea Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 81. India Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 82. India Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 83. Australia Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 84. Australia Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 85. Taiwan Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 86. Taiwan Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 87. Indonesia Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 88. Indonesia Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 89. Thailand Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 90. Thailand Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 91. Malaysia Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 92. Malaysia Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 93. Philippines Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 94. Philippines Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 95. Vietnam Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 96. Vietnam Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 97. Latin America Antibacterial (Drug) Resistance Sales Growth Rate 2016-2021 (K Units)
Figure 98. Latin America Antibacterial (Drug) Resistance Revenue Growth Rate 2016-2021 (US$ Million)
Figure 99. Latin America Antibacterial (Drug) Resistance Sales Market Share by Country in 2020
Figure 100. Latin America Antibacterial (Drug) Resistance Revenue Market Share by Country in 2020
Figure 101. Mexico Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 102. Mexico Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 103. Brazil Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 104. Brazil Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 105. Argentina Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units)
Figure 106. Argentina Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million)
Figure 107. Middle East and Africa Antibacterial (Drug) Resistance Sales Growth Rate 2016-2021 (K Units)
Figure 108. Middle East and Africa Antibacterial (Drug) Resistance Revenue Growth Rate 2016-
Keyplayers in Global and United States Antibacterial (Drug) Resistance Market Insights, Forecast to 2027
Melinta TherapeuticsAllergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO